▶ 調査レポート

世界の重症急性呼吸器症候群(SARS)治療薬市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界の重症急性呼吸器症候群(SARS)治療薬市場規模・現状・予測(2021年-2027年) / Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size, Status and Forecast 2021-2027 / QFJ1-4854資料のイメージです。• レポートコード:QFJ1-4854
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、97ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、重症急性呼吸器症候群(SARS)治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(CEL-1000、D-3252、FDX-000、INO-4500、LCA-60、その他)、用途別市場規模(病院、クリニック、研究センター)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・重症急性呼吸器症候群(SARS)治療薬の市場動向
・企業の競争状況、市場シェア
・重症急性呼吸器症候群(SARS)治療薬の種類別市場規模と予測2016-2027(CEL-1000、D-3252、FDX-000、INO-4500、LCA-60、その他)
・重症急性呼吸器症候群(SARS)治療薬の用途別市場規模と予測2016-2027(病院、クリニック、研究センター)
・重症急性呼吸器症候群(SARS)治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・重症急性呼吸器症候群(SARS)治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・重症急性呼吸器症候群(SARS)治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・重症急性呼吸器症候群(SARS)治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・重症急性呼吸器症候群(SARS)治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(CEL-SCI Corporation、GeneCure LLC、Humabs BioMed SA、Inovio Pharmaceuticals, Inc.、Nanotherapeutics, Inc.、Novavax, Inc.、Phelix Therapeutics, LLC、Protein Sciences Corporation)
・結論

Market Analysis and Insights: Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market
The global Severe Acute Respiratory Syndrome(SARS) Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market.

Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Scope and Market Size
Severe Acute Respiratory Syndrome(SARS) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others

Segment by Application
Hospital
Clinic
Research Center

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 CEL-1000
1.2.3 D-3252
1.2.4 FDX-000
1.2.5 INO-4500
1.2.6 LCA-60
1.2.7 Others
1.3 Market by Application
1.3.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Center
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Perspective (2016-2027)
2.2 Severe Acute Respiratory Syndrome(SARS) Therapeutics Growth Trends by Regions
2.2.1 Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Severe Acute Respiratory Syndrome(SARS) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Severe Acute Respiratory Syndrome(SARS) Therapeutics Industry Dynamic
2.3.1 Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Trends
2.3.2 Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Drivers
2.3.3 Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Challenges
2.3.4 Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Players by Revenue
3.1.1 Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue
3.4 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Concentration Ratio
3.4.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue in 2020
3.5 Severe Acute Respiratory Syndrome(SARS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Solution and Service
3.7 Date of Enter into Severe Acute Respiratory Syndrome(SARS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Severe Acute Respiratory Syndrome(SARS) Therapeutics Breakdown Data by Type
4.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Severe Acute Respiratory Syndrome(SARS) Therapeutics Breakdown Data by Application
5.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (2016-2027)
6.2 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type
6.2.1 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2027)
6.3 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application
6.3.1 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2027)
6.4 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country
6.4.1 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (2016-2027)
7.2 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type
7.2.1 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application
7.3.1 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country
7.4.1 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (2016-2027)
9.2 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type
9.2.1 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application
9.3.1 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country
9.4.1 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 CEL-SCI Corporation
11.1.1 CEL-SCI Corporation Company Details
11.1.2 CEL-SCI Corporation Business Overview
11.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.1.4 CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.1.5 CEL-SCI Corporation Recent Development
11.2 GeneCure LLC
11.2.1 GeneCure LLC Company Details
11.2.2 GeneCure LLC Business Overview
11.2.3 GeneCure LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.2.4 GeneCure LLC Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.2.5 GeneCure LLC Recent Development
11.3 Humabs BioMed SA
11.3.1 Humabs BioMed SA Company Details
11.3.2 Humabs BioMed SA Business Overview
11.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.3.4 Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.3.5 Humabs BioMed SA Recent Development
11.4 Inovio Pharmaceuticals, Inc.
11.4.1 Inovio Pharmaceuticals, Inc. Company Details
11.4.2 Inovio Pharmaceuticals, Inc. Business Overview
11.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.4.4 Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.4.5 Inovio Pharmaceuticals, Inc. Recent Development
11.5 Nanotherapeutics, Inc.
11.5.1 Nanotherapeutics, Inc. Company Details
11.5.2 Nanotherapeutics, Inc. Business Overview
11.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.5.4 Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.5.5 Nanotherapeutics, Inc. Recent Development
11.6 Novavax, Inc.
11.6.1 Novavax, Inc. Company Details
11.6.2 Novavax, Inc. Business Overview
11.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.6.4 Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.6.5 Novavax, Inc. Recent Development
11.7 Phelix Therapeutics, LLC
11.7.1 Phelix Therapeutics, LLC Company Details
11.7.2 Phelix Therapeutics, LLC Business Overview
11.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.7.4 Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.7.5 Phelix Therapeutics, LLC Recent Development
11.8 Protein Sciences Corporation
11.8.1 Protein Sciences Corporation Company Details
11.8.2 Protein Sciences Corporation Business Overview
11.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Introduction
11.8.4 Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
11.8.5 Protein Sciences Corporation Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of CEL-1000
Table 3. Key Players of D-3252
Table 4. Key Players of FDX-000
Table 5. Key Players of INO-4500
Table 6. Key Players of LCA-60
Table 7. Key Players of Others
Table 8. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Regions (2016-2021)
Table 12. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Regions (2022-2027)
Table 14. Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Trends
Table 15. Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Drivers
Table 16. Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Challenges
Table 17. Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Restraints
Table 18. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Players (2016-2021)
Table 20. Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics as of 2020)
Table 21. Ranking of Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Solution and Service
Table 25. Date of Enter into Severe Acute Respiratory Syndrome(SARS) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Type (2016-2021)
Table 29. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Application (2016-2021)
Table 33. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 65. CEL-SCI Corporation Company Details
Table 66. CEL-SCI Corporation Business Overview
Table 67. CEL-SCI Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 68. CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 69. CEL-SCI Corporation Recent Development
Table 70. GeneCure LLC Company Details
Table 71. GeneCure LLC Business Overview
Table 72. GeneCure LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 73. GeneCure LLC Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 74. GeneCure LLC Recent Development
Table 75. Humabs BioMed SA Company Details
Table 76. Humabs BioMed SA Business Overview
Table 77. Humabs BioMed SA Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 78. Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 79. Humabs BioMed SA Recent Development
Table 80. Inovio Pharmaceuticals, Inc. Company Details
Table 81. Inovio Pharmaceuticals, Inc. Business Overview
Table 82. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 83. Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 84. Inovio Pharmaceuticals, Inc. Recent Development
Table 85. Nanotherapeutics, Inc. Company Details
Table 86. Nanotherapeutics, Inc. Business Overview
Table 87. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 88. Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 89. Nanotherapeutics, Inc. Recent Development
Table 90. Novavax, Inc. Company Details
Table 91. Novavax, Inc. Business Overview
Table 92. Novavax, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 93. Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 94. Novavax, Inc. Recent Development
Table 95. Phelix Therapeutics, LLC Company Details
Table 96. Phelix Therapeutics, LLC Business Overview
Table 97. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Product
Table 98. Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 99. Phelix Therapeutics, LLC Recent Development
Table 100. Protein Sciences Corporation Company Details
Table 101. Protein Sciences Corporation Business Overview
Table 102. Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021) & (US$ Million)
Table 103. Protein Sciences Corporation Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. CEL-1000 Features
Figure 3. D-3252 Features
Figure 4. FDX-000 Features
Figure 5. INO-4500 Features
Figure 6. LCA-60 Features
Figure 7. Others Features
Figure 8. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Research Center Case Studies
Figure 12. Severe Acute Respiratory Syndrome(SARS) Therapeutics Report Years Considered
Figure 13. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 16. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Regions (2022-2027)
Figure 17. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Players in 2020
Figure 18. Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Severe Acute Respiratory Syndrome(SARS) Therapeutics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue in 2020
Figure 20. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 21. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 22. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type (2016-2027)
Figure 24. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application (2016-2027)
Figure 25. North America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type (2016-2027)
Figure 30. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application (2016-2027)
Figure 31. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Country (2016-2027)
Figure 32. Germany Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Region (2016-2027)
Figure 42. China Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type (2016-2027)
Figure 50. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application (2016-2027)
Figure 51. Latin America Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Country (2016-2027)
Figure 52. Mexico Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Share by Country (2016-2027)
Figure 58. Turkey Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. CEL-SCI Corporation Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 62. GeneCure LLC Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 63. Humabs BioMed SA Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 64. Inovio Pharmaceuticals, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 65. Nanotherapeutics, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 66. Novavax, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 67. Phelix Therapeutics, LLC Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 68. Protein Sciences Corporation Revenue Growth Rate in Severe Acute Respiratory Syndrome(SARS) Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed